

Press release

Synairgen plc (‘Synairgen’ or the ‘Company’)

Notice of Interim Results

Southampton, UK – 21 September 2021: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, will announce its unaudited half-year report for the six months ended 30 June 2021 on Thursday 30 September 2021.

A webcast and Q&A session for analysts will be hosted by Synairgen’s management team at 13:00 BST on 30 September 2021. Analysts should contact Consilium Strategic Communications for further details on synairgen@consilium-comms.com.

A recording of the webcast will be made available via the Investors section of the Company’s website at www.synairgen.com later in the day.

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Brooke Clarke, Head of Communications
Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700

MKC Strategies, LLC (US Media Relations)

Mary Conway
MConway@MKCStrategies.com
Tel: +1 516 606 6545

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory biotechnology company focused on drug discovery, development and commercialisation. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. Granted Fast Track status from the US Food and Drug Administration (FDA) and deemed an Urgent Public Health study by the UK’s National Institute for Health Research (NIHR), Synairgen’s Phase III clinical programme is currently evaluating nebulised SNG001 in patients across 17 countries. In a Phase II trial in hospitalised COVID-19 patients, SNG001 demonstrated a greater than twofold chance of recovery to ‘no limitation of activities’ versus placebo.

Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.